The literature-to-lab gap in biomedical R&D

Most drug discovery teams operate with two disconnected information systems. On one side, there is the published literature: over 1.5 million new biomedical papers per year indexed in PubMed alone. On the other, there is the internal experimental record: assay results, instrument outputs, compound registries, workflow logs.

The problem is structural. Lab operations platforms manage internal data well. Literature tools like PubMed provide keyword-based search over abstracts. But no single platform bridges the two, meaning researchers design experiments without systematically engaging with the full-text evidence that could prevent redundant work, identify known confounders, or surface conflicting findings.

A 2024 international survey of 1,630 biomedical researchers found that 72% agreed there is a reproducibility crisis in biomedicine, with "pressure to publish" cited as the leading perceived cause (PMID: 39499707). But publication pressure is only part of the story. Insufficient literature engagement before experiment design is a contributing factor that platform architecture can address.

What Dotmatics Luma does: lab operations and data management

Dotmatics Luma is a Scientific Intelligence Platform built for the internal data layer of R&D. It connects instruments, manages lab workflows, structures experimental data across teams, and automates repetitive operational tasks. Think of it as the digital backbone of a wet lab or R&D department.

Its core capabilities include: adaptive workflow automation for lab processes; Lab Connect for automated instrument data ingestion; material and ontology management with full traceability; electronic lab notebooks (ELN) for experiment recording; and specialised modules for flow cytometry (OMIQ, FCS Express), proteomics (Protein Metrics), bioinformatics (SnapGene, Geneious Prime, Geneious Biologics), cheminformatics (Vortex), and statistical analysis (GraphPad Prism).

Luma recently introduced Luma Agent, an agentic AI layer that can configure dashboards, query internal experimental databases, and generate audit-ready reports. The platform targets enterprise pharma, chemicals, and materials companies, with customers including Pfizer, Sanofi, Merck, BASF, Moderna, and NASA. Dotmatics has signed a definitive agreement to be acquired by Siemens.

Luma's architecture aligns with the FAIR data principles (Findable, Accessible, Interoperable, Reusable) articulated by Wilkinson et al. in 2016 (PMID: 26978244). These principles emphasise machine-actionable data stewardship, and Luma's structured data model, ontology management, and instrument integration are built to serve that goal for internal experimental data.

What BioSkepsis does: literature intelligence for biomedical researchers

BioSkepsis operates on a fundamentally different data layer: the published literature. It searches 40M+ full-text biomedical papers (1931 to present, updated weekly) and generates citation-grounded answers to natural-language research questions. Every claim traces back to the exact passage in the original paper, not to an abstract and not to a hallucinated reference.

The retrieval system is biology-native, built on Gene Ontology, MeSH terms, gene identifiers, and domain-specific keywords rather than raw text similarity. This matters because biomedical language is dense with synonymy (TP53 / p53 / tumour protein p53) and polysemy (terms like "expression" or "differentiation" mean different things in different biological contexts).

Beyond search, BioSkepsis generates: narrative syntheses of research landscapes; citation network analysis identifying foundational, hub, bridge, and novel papers; detection of emerging trends where 50%+ of high-impact publications are from the last three years; mechanistic link tables across selected papers; and testable hypotheses with corresponding experimental designs.

The platform is priced for individual researchers and small teams: free (Basic), EUR 8/month (Plus), EUR 35/month (Pro), and EUR 60/seat/month (Team). It exports to PDF, DOCX, Markdown, JSON, and standard reference formats (APA, BibTeX, RIS), with direct Zotero integration.

Side-by-side: Luma vs BioSkepsis across R&D dimensions

Why complementarity matters for reproducibility in biomedical research

The reproducibility problem in biomedical research is not purely a lab operations problem. A 2019 guide to reproducibility in preclinical research argued that improving reproducibility requires more explicit data analysis plans, detailed experimental protocols, and active laboratory management practices (PMID: 29995667). Luma addresses many of these requirements through structured workflows, audit trails, and instrument integration.

But there is a prior step that lab platforms do not cover: understanding what the existing literature says about the system you are about to study. If three published papers already show conflicting results on a given target-ligand interaction, and a researcher designs an assay without knowing this, the resulting data may reproduce the confusion rather than resolve it.

This is where BioSkepsis sits. By reading full-text papers rather than abstracts, it surfaces methodological details, conflicting findings, and known confounders that keyword-based search misses. A researcher who runs a BioSkepsis synthesis before designing an experiment enters the lab with a map of what is known, what conflicts, and where the genuine gaps are.

Who should use which platform in a biomedical R&D team

The digital lab in pharmaceutical research needs both layers

The pharmaceutical industry is investing heavily in digital transformation of R&D. Rudmann et al. (2023) described a roadmap for AI-augmented nonclinical pathology laboratories that integrates LIMS, whole-slide scanners, and deep-learning decision support (PMID: 37598916). This is the kind of infrastructure that Luma provides.

But a 2025 systematic review in JAMA found that existing evaluations of large language models in health care overwhelmingly focus on accuracy of question-answering for medical examinations, with limited attention to real-world clinical data integration, fairness, or deployment considerations (PMID: 39405325). The same gap applies to R&D: most AI tools operate on either internal data or published knowledge, but not both in a structured way.

The complementarity thesis is simple. Luma makes internal experimental data FAIR-compliant, structured, and traceable. BioSkepsis makes the published literature searchable, synthesisable, and actionable at the level of biological mechanism. A pharma team that uses both has a closed loop: literature informs experiment design; experimental results are structured and recorded; new findings feed back into the literature landscape.

Neither platform alone closes this loop. That is the case for complementarity.

Frequently asked questions